secwatch.observer — SEC 8-K summary
======================================

Issuer:     Equillium, Inc. (EQ)
CIK:        0001746466
Form:       8-K
Filed at:   2025-04-24T23:59:59+00:00
Accession:  0001193125-25-092435
Event type: regulatory
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Equillium announces FDA declined Breakthrough Therapy and Accelerated Approval for itolizumab in aGVHD
--------------------------------------------------------------------------------

- FDA declined Breakthrough Therapy designation and Accelerated Approval for itolizumab in aGVHD based on EQUATOR study data.
- FDA focused on Day 29 outcomes; itolizumab did not show improvement by Day 29 despite favorable safety and longer-term data.
- Company plans to accelerate closure of EQUATOR study and evaluate options to advance or partner itolizumab.
- Cash and equivalents $14.5M as of March 31, 2025; expected to fund operations into Q3 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1746466/000119312525092435/0001193125-25-092435-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1746466/000119312525092435/d787196d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-092435

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer